Mipomersen - Kastle Therapeutics

Drug Profile

Mipomersen - Kastle Therapeutics

Alternative Names: ISIS-301012; Kynamro; Mipomersen sodium

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Genzyme Corporation; Isis Pharmaceuticals; Kastle Therapeutics
  • Class Antihyperlipidaemics; Antisense oligonucleotides; Oligodeoxyribonucleotides
  • Mechanism of Action Apolipoprotein B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa
  • Phase III Hypercholesterolaemia
  • No development reported Atherosclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Dec 2017 Mipomersen market licensed to TRPharm in Middle East and Turkey
  • 26 Jul 2017 Phase-III development for Heterozygous Familial Hypercholesterolaemia (Adjunctive treatment) is ongoing in countries worldwide (SC) (Kastle Therapeutics website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top